The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Diabetic kidney disease: a report from an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1296 · Cited by 1,153
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Cited by
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
Lawton, J. S., Tamis-Holland, J. E., Bangalore, S., Bates, E. R., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.006 · Cited by 1,558
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Lawton, J. S., Tamis-Holland, J. E., Bangalore, S., Bates, E. R., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001038 · Cited by 829
Kenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
Rosenstock, J., Allison, D., Birkenfeld, A. L., Blicher, T. M., Deenadayalan, S., Jacobsen, J. B., Serusclat, P., Violante, R., Watada, H., Davies, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.2942 · Cited by 421
Ueda, P., Svanström, H., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2018) · BMJ · doi:10.1136/bmj.k4365 · Cited by 367
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 363
Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13648 · Cited by 330
Młynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031094 · Cited by 328
Ren, H., Shao, Y., Wu, C., Ma, X., Lv, C., & Wang, Q. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110628 · Cited by 313
Segar, M. W., Vaduganathan, M., Patel, K. V., McGuire, D. K., Butler, J., Fonarow, G. C., Basit, M., Kannan, V., Grodin, J. L., Everett, B., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0587 · Cited by 299
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311588 · Cited by 286
Leptin, cardiovascular diseases and type 2 diabetes mellitus
Katsiki, N., Mikhailidis, D. P., & Banach, M. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.40 · Cited by 285
Silbert, R., Salcido-Montenegro, A., Rodriguez-Gutierrez, R., Katabi, A., & McCoy, R. G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1018-0 · Cited by 229
Khunti, S., Khunti, K., & Seidu, S. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819844694 · Cited by 182
Apolzan, J. W., Venditti, E. M., Edelstein, S. L., Knowler, W. C., Dabelea, D., Boyko, E. J., Pi-Sunyer, X., Kalyani, R. R., Franks, P. W., Srikanthan, P., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-1605 · Cited by 156
Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S., & Targher, G. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.12.007 · Cited by 138
Diabetes Management in the Elderly
Leung, E., Wongrakpanich, S., & Munshi, M. N. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0033 · Cited by 131
Andreozzi, F., Candido, R., Corrao, S., Fornengo, R., Giancaterini, A., Ponzani, P., Ponziani, M. C., Tuccinardi, F., & Mannino, D. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00559-7 · Cited by 128
Mody, R., Huang, Q., Yu, M., Zhao, R., Patel, H., Grabner, M., & Landó, L. F. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13603 · Cited by 93
Semaglutide: review and place in therapy for adults with type 2 diabetes
Goldenberg, R. M., & Steen, O. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.05.008 · Cited by 91
Hussein, H., Zaccardi, F., Khunti, K., Davies, M. J., Patsko, E., Dhalwani, N. N., Kloecker, D. E., Ioannidou, E., & Gray, L. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14008 · Cited by 82
Romera, I., Cebrián-Cuenca, A., Álvarez-Guisasola, F., Gomez-Peralta, F., & Reviriego, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0535-9 · Cited by 77
Lynam, A., McDonald, T., Hill, A., Dennis, J., Oram, R., Pearson, E., Weedon, M., Hattersley, A., Owen, K., Shields, B., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031586 · Cited by 72
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes
Limonte, C. P., Hall, Y. N., Trikudanathan, S., Tuttle, K. R., Hirsch, I. B., de Boer, I. H., & Zelnick, L. R. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108204 · Cited by 58
McEwan, P., Bennett, H., Khunti, K., Wilding, J., Edmonds, C., Thuresson, M., Wittbrodt, E., Fenici, P., & Kosiborod, M. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14162 · Cited by 58
Lauffenburger, J. C., Ghazinouri, R., Jan, S., Makanji, S., Ferro, C. A., Lewey, J., Wittbrodt, E., Lee, J., Haff, N., Fontanet, C. P., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0214754 · Cited by 50
Maiorino, M. I., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Esposito, K., & Giugliano, D. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13343 · Cited by 52
Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., Azoulay, L., & Patorno, E. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15196 · Cited by 39
Khera, R., Schuemie, M. J., Lu, Y., Ostropolets, A., Chen, R., Hripcsak, G., Ryan, P. B., Krumholz, H. M., & Suchard, M. A. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057977 · Cited by 37
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
Wong, J. C., Izadi, Z., Schroeder, S., Nader, M., Min, J., Neinstein, A. B., & Adi, S. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0251 · Cited by 29
Shi, F.-H., Li, H., Shen, L., Zhang, Z., Jiang, Y.-H., Hu, Y.-M., Liu, X.-Y., Gu, Z.-C., Ma, J., & Lin, H.-W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01066 · Cited by 30
Gao, L., Huang, H., Zhang, L., Zhang, N., Fu, Y., Zhu, D., Bi, Y., & Feng, W. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1608-0345 · Cited by 24
Kawaguchi, Y., Sawa, J., Hamai, C., Nishimura, Y., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13038 · Cited by 10
Disparities in adoption of new diabetic therapies with cardiovascular benefits
Vasti, E. C., Basina, M., Calma, J., Maron, D. J., Rodriguez, F., & Sandhu, A. T. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110233 · Cited by 11
Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016
Zhao, J. Z., Weinhandl, E. D., Carlson, A. M., & St. Peter, W. L. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2020.09.016 · Cited by 9
Glycemic control and its factor in type 2 diabetic patients in Jakarta
Maifitrianti, M., Wulandari, N., Haro, M., Lestari, S. F., & Fitriani, A. (2020) · Indonesian Journal of Clinical Pharmacy · doi:10.15416/ijcp.2020.9.3.198 · Cited by 6
Effectiveness of nursing interventions in the control of type 2 diabetes mellitus
(2020) · Anales del Sistema Sanitario de Navarra · doi:10.23938/assn.0860 · Cited by 6
Metadata
- Authors
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-11-24
- Volume
- 41
- Issue
- Supplement_1
- Pages
- S73-S85
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4256525495
- Cited by
- 699
- References
- 53
- FWCI
- 90.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.